Matches in Nanopublications for { ?s ?p "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1231386.RADfylsUXa4TGPgiUBaXV41Wha96H9zMnu8kZfVrKyPZo130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231386.RADfylsUXa4TGPgiUBaXV41Wha96H9zMnu8kZfVrKyPZo130_provenance.
- NP1231384.RASs6hSq6uoPNiPqgCXCZ5ocsaEizGlfTGYWfRq1SukAY130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231384.RASs6hSq6uoPNiPqgCXCZ5ocsaEizGlfTGYWfRq1SukAY130_provenance.
- NP1231388.RAXdITB2h4641X94IIB8YDrdtE6Et8S1xQJVW8FZA7qFg130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231388.RAXdITB2h4641X94IIB8YDrdtE6Et8S1xQJVW8FZA7qFg130_provenance.
- NP1231389.RAQzstfEWxr4kREataRLmvHOuuBQZibIB7Puxd-Rz2hwg130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231389.RAQzstfEWxr4kREataRLmvHOuuBQZibIB7Puxd-Rz2hwg130_provenance.
- assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1231385.RAGXP_vgzrZsIJ4suvd--USbTILBRj_Kn7p6fx8lh0OTo130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231385.RAGXP_vgzrZsIJ4suvd--USbTILBRj_Kn7p6fx8lh0OTo130_provenance.
- NP1231387.RA1jNhlGSDHRPjzane_RM3qivbfeXz5lLpPctZIFXMpbY130_assertion description "[To define the extent of the in vivo pluripotency network in this system, we ranked all TFs in the GCT(Net) according to sharing of ARACNe-predicted targets with those of POU5F1 and NANOG using an odds-ratio analysis method.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231387.RA1jNhlGSDHRPjzane_RM3qivbfeXz5lLpPctZIFXMpbY130_provenance.